Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting
09:00 EDT 7 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Trevena, Inc., the leader in the discovery of G-protein coupled receptor
(GPCR) biased ligands, today announced that it is presenting a poster
featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart
Failure Society of...
Other Sources for this Article
Trevena, Inc.
Alastair Southwell, 610-354-8840
asouthwell@trevenainc.com
More From BioPortfolio on "Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
